Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 3

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Center for International Blood and Marrow Transplant Research · with National Marrow Donor Program · NCT00785525

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–60 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 3
Target enrollment
60000
US sites recruiting
4
Study start
February 1997
Record last updated
April 13, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of the study is to

  • Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors
  • Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis
  • Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant recipients
  • Determine the acceptability of stem cell donation by filgrastim stimulated apheresis in normal donors

Being studied: Filgrastim

Conditions: Healthy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • PBSC donors must meet the same criteria as NMDP marrow donors. These criteria are set forth in the Donor Center Manual of Operations.
  • Confirmatory pregnancy test must be performed within 15 days of collection and prior to the start of filgrastim administration; this may require more than one test to be performed.

Exclusion Criteria

  • Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose.
  • Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
  • History of autoimmune disorders, including rheumatic diseases and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable.
  • History of deep vein thrombosis or pulmonary embolism.
  • History of iritis or episcleritis.
  • Thrombocytopenia \< 150 x 10\^9/L (\< 150,000/uL) at baseline evaluation.
  • Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been fully evaluated.
  • Positive Hemoglobin-Solubility (e.g., SickleDex or equivalent) test.
  • Donors receiving experimental therapy or investigational agents.
  • Positive pregnancy test collected/reported prior to start of filgrastim.

Recruiting US locations

Study contacts (from the official record)

  • Lisa Erickson · PBSCStudyTeam@nmdp.org
All healthy volunteers studies in Florida →
Filgrastim-Mobilized Stem Cells for Transplantation Using… (NCT00785525) | Bored Studies